Research and Innovation Research and Innovation An Overview of European Commission Activities on Infectious Diseases Ole Olesen Unit Infectious Diseases.

Slides:



Advertisements
Similar presentations
1 Science Technology and Innovation in the chemicals sector: the role of SusChem Andrea Tilche European Commission DG Research Head of the Unit « Environmental.
Advertisements

Policy officer, Balkans & Turkey Research and Innovation DG
Research Leaders: Meeting the challenge Mark Walport 19 November 2008.
Story of an Essential Resolution The WHO Resolution on A Global Framework on Essential Health R&D.
Multinational Comparisons of Health Systems Data, 2008 Support for this research was provided by The Commonwealth Fund. The views presented here are those.
1. 2 European Science Events Association [Eusea pronounced as you see] Peter Rebernik, Eusea Executive Director Vienna, Austria Version:
The Swedish Energy Agency The energy system and the sustainable municipality programme 1 Johan Burström Programme manager.
Seminar "Open Government in the Making" Brussels, 4 October 2012 Andrea Halmos European Commission, DG CONNECT Unit H3 Public Services.
Presentation to Romania Tudor Constantinescu DG ENER 19 July 2011 Excellent Research Boosting Innovation Creating Jobs FP7 Work Programme 2012.
Eurobarometer 77.2 The Crisis and Economic Governance (V) Survey commissioned by the European Parliament and co-ordinated by Directorate-General for Communication.
GROWING REGIONS, GROWING EUROPE Fourth Report on Economic and Social Cohesion By Prof. Danuta Hübner Brussels, 30 May 2007.
1 R&D Financing Possibilities Philippe Quevauviller Date: 20/03/2013 Enterprise and Industry.
DG REGIO – Unit "Thematic Development" EUROPEAN COMMISSION EN 1 Transport and Regional Policy Transport and Regional Policy Patrick.
REALISING BOSNIA AND HERZEGOVINAS EUROPEAN POTENTIAL: FROM WAR ECONOMY TO CREDITWORTHINESS AND SUSTAINABILITY MACRO AND FISCAL FRAMEWORK Ljerka Marić,
AdministrationTo researchers, students, farmers, NGOs, SMEs, regions… Of the budget funds policies and projects in Member States and beyond FOR 500 MILLION.
1 Cohesion Policy support for Sustainable Energy Brussels, 11 October 2011 Maud SKÄRINGER European Commission Directorate-General for Regional Policy.
Investing in Europes future Gathering participants, the OPEN DAYS is the annual key event for EU, national, regional and local.
Pre-commercial Procurement of Innovation Building together innovative solutions Ulf Dahlsten, Director European Commission, DG INFSO.
1 Cohesion Policy Investing in Energy Efficiency in Buildings, Brussels November 2011 Patrice Millet Industrial Technologies DG Research and Innovation.
Pavel Exner Member of the European Research Council Scientific Council Research Connection Prague, 7 May 2009 FP7 IDEAS Programme The European Research.
1 Irregularities statistics from draft 280 Annual Fight Against Fraud Report for 2008 Maria NTZIOUNI-DOUMAS OLAF Train the trainers European Commission.
1. 2 Why are Result & Impact Indicators Needed? To better understand the positive/negative results of EC aid. The main questions are: 1.What change is.
European Commission Enterprise and Industry Social innovation: How innovation policy can empower people, entrepreneurs and society Henriette van Eijl,
Regional Policy EUROPEAN COMMISSION Regions delivering Lisbon through Cohesion Policy Press Briefing by Regional Policy Commissioner Prof. Danuta.
EUROPEAN COMMISSION Community health programmes: first results and future challenges for the EU regions Donata Meroni European Commission - DG Health and.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD A report prepared by WHO for the Netherlands Government by Warren Kaplan Richard Laing and Saloni TannaMarjolein.
1 RA I Sub-Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Casablanca, Morocco, 20 – 22 December 2005 Status of observing programmes in RA I.
Research and Innovation Research and Innovation Results of the 2012 Survey on R&D investment and policy measures Pierre Vigier DG Research and Innovation.
1 The EPO Co-operation Programme to reorient patent information centres Heidrun Krestel European Affairs, Member States 4 October 2010.
Tennessee Higher Education Commission Higher Education Recommendations & Finance Overview November 15, 2012.
CALENDAR.
FACTORING ax2 + bx + c Think “unfoil” Work down, Show all steps.
No Goals at Half-time: What Next for the Millennium Development Goals? Goal 6: Combating HIV/AIDS, malaria and other diseases John Porter.
What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010.
European Commission – Directorate-General Communication 1 Lessons learned from the European Year of Volunteering Preparations for the European.
Responses to infectious diseases among people who inject drugs: Policies and measures taken in Europe Dagmar Hedrich, EMCDDA Project Imp.Ac:T - Improving.
Break Time Remaining 10:00.
Erasmus+ Erasmus+: Sport Yves Le LostecqueDG Education and Culture Head of the Sport UnitEuropean Commission.
PP Test Review Sections 6-1 to 6-6
EU Market Situation for Eggs and Poultry Management Committee 21 June 2012.
1 YOUTH POLICY SYMPOSIUM Odessa, July 2011 Sergej KOPERDAK Head of Unit, Youth Policy DG Education and Culture European Commission.
Opioid-Related Deaths and Mortality Rates by County, Wisconsin Residents Office of Health Informatics and AIDS/HIV and Hepatitis C Program Bureau.
Copyright © 2012, Elsevier Inc. All rights Reserved. 1 Chapter 7 Modeling Structure with Blocks.
Findings from a survey of HGIEs in eight countries and policy implications Mutual Learning Seminar Session II: Policies to support high-growth innovative.
From DOTS to the Stop TB Strategy Building on Achievements for Future Planning Stop TB Partnership Symposium at the 37 th UNION World Conference on TB.
Involving all health care providers in collaborative TB/HIV activities Eva Nathanson PPM subgroup meeting Cairo, Egypt, 3-5 June 2008.
Trends in TB R&D investment: Where is funding most needed? Lindsey Wu Policy Analyst Policy Cures
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
Christina Skantze. Baltic Sea Strategy initiative – why? New political context for cooperation – EU-enlargement, integration Underline priorities and.
Stakeholders meeting for priority medicines for Europe and the world Role of Public Private Partnerships 4 October 2004 Brussels Dr. Frans Van den Boom,
TB/HIV epidemic in the Western Cape Update 23 February 2010 Nathea Nicolay Programme Director: Health.
Research and Innovation Research and Innovation Results of the 2012 Survey on R&D investment and policy measures Pierre Vigier DG Research and Innovation.
 Prevents 14 million cases of disease in the US each year  Objectives reflect a mobile world society  People continue to contract diseases that are.
©Brooks/Cole, 2001 Chapter 12 Derived Types-- Enumerated, Structure and Union.
PSSA Preparation.
1 JCB 30 June 20, 2007 Vision and Strategy Robert Ridley TDR Business Plan Fostering an effective global research effort on infectious diseases.
EU meat sectors: Current issues and perspectives Juan Fernández Martín Head of Unit "Animal Products" DG Agriculture and Rural Development, European Commission.
Changes in Donor Financing Over Time: A Global Perspective International AIDS Economics Network Pre-Conference Meeting Jen Kates, PhD July 19, 2014 Vice.
7 th Framework Programme (FP7) - Malta’s participation th January 2013 Anthea Fabri FP7 National Coordinator Malta Council for Science and.
1 EDCTP THE NEXT DECADE: Towards a Collaborative ERA fighting AIDS, malaria, tuberculosis & tropical diseases Proposal for EDCTP-II to the European Council.
Title of Presentation 1 EU-ASEAN S&T cooperation to jointly tackle societal challenges Opportunities for future EU-ASEAN collaborations.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
1 EU-funded health research activities against TB: FP6 actions and perspectives toward FP7 DG Research - European Commission 22 MARCH 2007.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
CIS-Workshop on „WFD and Hydropower“ June 2007 Berlin, Germany - First Workshop under Phase II ( ) of the EU activity „Water Framework Directive.
Energy Union: an integrated approach to R&I
Work Programme The social challenge “Health, Demographic Change and Wellbeing” Maia Okujava NCP for Health, Demographic Change and weii-being,
The Commission Strategy on TB vaccine research
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Presentation transcript:

Research and Innovation Research and Innovation An Overview of European Commission Activities on Infectious Diseases Ole Olesen Unit Infectious Diseases and Public Health Directorate-General for Research and Innovation European Commission STOA – Aviesan Workshop, Bruxelles – 19 June 2012

Policy Research and Innovation Research and Innovation The role of the European Commission - Research and innovation Develop and implement the European research and innovation policy agreed by the European Parliament and European Council. Funds research through multi-annual framework programmes for research (since 1984). billion 7th Framework Programme ( ) has a total budget of 53 billion - 4% of the total EU budget. The European Commission manages about 5% of total public spending in R&D in the European Union.

Policy Research and Innovation Research and Innovation Total funding: 53 billion The 7 th EU Framework Programme ( )

4 EU27 The power of collaboration

Policy Research and Innovation Research and Innovation Main policy drivers: Improving health of European citizens Increasing competitiveness of European health- related industries Global health issues, incl. emerging epidemics

Policy Research and Innovation Research and Innovation Objectives for Infectious Diseases in FP7: to improve prevention, diagnostics and treatment of infectious diseases by supporting scientific collaboration between Countries Sectors – public and private Area of research Approximate annual average budget for infectious diseases in FP7: 100 million

Policy Research and Innovation Research and Innovation Key priorities for infectious diseases in the Health Theme Emerging infectious diseases Influenza and other emerging diseases (incl vector-borne diseases) Anti-microbial resistance Poverty-related diseases HIV/AIDS, Tuberculosis, malaria Neglected Infectious diseases

Policy Research and Innovation Research and Innovation Distribution in FP7 – so far Emerging infectious diseases (incl. influenza) Projects: 29 EU contribution: 141 M Antimicrobial resistance Projects: 26 EU contribution: 131 M HIV/AIDS, malaria, tuberculosis Projects: 51 EU contribution: 206 M Neglected infectious diseases Projects: 15 EU contribution: 65 M

Policy Research and Innovation Research and Innovation FP7-funded projects on antimicrobial resistance Bacterial infections:20 projects Viral infections: 7 projects Protozoan infections: 4 projects Fungal infections: 1 project 26 projects in the Health Theme: 131 Mio EU Research on Antimicrobial Resistance presents a selection of these projects: >>Infectious Diseases >>Anti-Microbial Drug Resistance

Policy Research and Innovation Research and Innovation Co-operation between EU Member States: Joint programming on AMR Pulls together national research efforts, uses public resources better, and tackles key common challenges Initiative lead by Sweden 18 Countries BE, CH, CZ, DE, DK, ES, FI, FR, GR, IL, IT, NL, NO, PL, RO, SE,TK and UK involved Only 2 countries (DE and NL) have earmarked programmes for AMR research funding – the others fund AMR research as a result of bottom-up competition. Development of a common vision and strategic research agenda – expected this year Implementation of joint activities in 2013?

Policy Research and Innovation Research and Innovation Emerging infectious diseases (including influenza) 29 projects with total EC funding of 141M 16 projects exclusively on human influenza 49M 3 projects on influenza and other emerging pathogens 36M 10 projects on emerging diseases excluding influenza 56M

Policy Research and Innovation Research and Innovation Disease burden (DALY/year 1000s) Global prevalence Annual deaths million1.8 million WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva UNAIDS World AIDS day report, 2011 Key goals in HIV/AIDS research: 18 projects, 84million Basic science3 projects, 1.5M Drug discovery3 projects, 8.5M Vaccines5 projects, 32.0M Microbicides1 projects, 12.5M Diagnostics2 projects, 2.0M Clinical management/treatment4 projects, 24.0M Overarching ERA-NET1 project, 2.0M HIV / AIDS

Policy Research and Innovation Research and Innovation Tuberculosis Disease burden (DALY/year 1000s) Global prevalence Annual deaths million1.464 million Key goals in tuberculosis research: 15 projects, 66 million Basic science/host-pathogen interaction7 projects, 14.5M Drug discovery3 projects, 21.0M Vaccines2 projects, 12.5M Diagnostics2 projects, 6.0M Clinical management/public health1 project, 12.0M WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.

Policy Research and Innovation Research and Innovation Disease burden (DALY/year 1000s) Global prevalen ce Annual deaths million Key goals in malaria research: 18 projects, 56million Basic science/host-pathogen interaction4 projects, 20.3M Vector research5 projects, 20.8M Drug discovery3 projects, 4.6M Vaccines5 projects, 7.4M Diagnostics1 project, 2.8M Malaria WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.

Policy Research and Innovation Research and Innovation Neglected infectious diseases Priority diseaseDisease burden (DALY/year 1000s) Global prevalence Annual deaths Leishmaniasis million Sleeping sickness 1673< Chagas disease million Key goals in NID research: 15 projects, 65M Protozoa (Leishmaniasis, Sleeping sickness, Chagas) Bacteria ( Buruli Ulcer, Diarrhoeal diseases) Helminths ( Schistosomiasis, Onchocerciasis, Filariasis) Basic immunology5 projects, 13.1M Vector control/public health7 projects, 10.5M Drug discovery6 projects, 11.0M Vaccines7 projects, 25.7M Diagnostics3 projects, 4.7M WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva. Hotez et al. (2009) Lancet 373:

Policy Research and Innovation Research and Innovation Collaborative projects improves the European Research Infrastructure Consist of 23 beneficiaries from 16 countries + more than 100 collaborating centres Access to data from over 250,000 HIV positive people 16 Coordinator: Prof. Kholoud Porter, MRC clinical trials unit, London, UK EU contribution: 12 M Unique resource

Policy Research and Innovation Research and Innovation European Developing Countries Clinical Trials Partnership (EDCTP) Public-Public Partnership: Joint initiative between 16 Member States and European Commission, established under art. 185 Independent legal entity (EEIG) Coordination of European national programmes for clinical trials in Africa for HIV/AIDS, malaria, TB EC contribution of 200 mill Euro + MS contribution of 200 mill Euro Launched in 2004, to be renewed 2014 (EDCTP-2) M

Policy Research and Innovation Research and Innovation Innovative Medicines Initiative (IMI) Public-private partnership, initiative under Article 187 Collaboration between EC and the European Federation of Pharmaceutical Industries and Associations (EFPIA) as a Joint Technology Initiative under FP7 Objective: to make drug discovery and development more efficient; to bring better medicines faster to patients; and to attract research investment to Europe Support / Funding of research activities following open Calls and independent review 18

Policy Research and Innovation Research and Innovation Next steps… FP7 Next call for proposals under Health (to be published in July 2012) contains new opportunities for building research infrastructures Large Topics (EU contribution up to 24 M Euro) on "Clinical management of patients in severe epidemics" Medium-sized topic (EU contribution up to 6 M Euro) on "Drug discovery platform for neglected parasitic diseases"

20 Research and Innovation Research and Innovation Horizon 2020 The EU Framework Programme for Research and Innovation THE Future

Research and Innovation Research and Innovation Three priorities: 1.Excellent science ( 30%) 2.Industrial leadership ( 30%) 3.Societal challenges ( 40%) Commission has proposed 80 billion budget for Legislative decision by MS and EP during Horizon 2020 will start 1 January 2014

Policy Research and Innovation Research and Innovation Among the Societal Challenges identified : HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING How to provide better health, while maintaining an economically sustainable healthcare system ? More health for the money !

Policy Research and Innovation Research and Innovation HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING Main Specific Research Lines Considered Effective health promotion and disease prevention Understanding the determinants of health, improving health promotion and disease prevention Developing effective screening programmes and improving the assessment of disease susceptibility Improving surveillance and preparedness of infectious diseases Developing better preventive vaccines and evidence-based vaccination schemes

Policy Research and Innovation Research and Innovation HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING Main Specific Research Lines Considered Manage, treat and cure diseases and disabilities Understanding disease Improving diagnosis Using in-silico medicine for improving disease management and prediction Treating disease Transferring knowledge to clinical practice Individual empowerments for self-management of health and integrated care

Policy Research and Innovation Research and Innovation HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING Main Specific Research Lines Considered Translating research into better healthcare Better use of health data Improving scientific tools and methods to support policy making and regulatory needs Active ageing, independent and assisted living Optimising the efficiency and effectiveness of healthcare systems and reducing inequalities

Research and Innovation Research and Innovation Thank you European Commission DG Research and Innovation Infectious Diseases and Public Health